EICHOR
● Active Not Recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Condition: Primary Prevention of Atherosclerotic Cardiovascular Disease · Sponsor: Novartis Pharmaceuticals
About this study
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (983)
| Central Alabama Research | Birmingham, Alabama, United States | — |
| UAB St Vincents | Birmingham, Alabama, United States | — |
| Eastern Shore Research Institute | Fairhope, Alabama, United States | — |
| G and L Research LLC | Foley, Alabama, United States | — |
| Longwood Research | Huntsville, Alabama, United States | — |
| CB Flock Corporation | Mobile, Alabama, United States | — |
| The Center for Clinical Trials | Saraland, Alabama, United States | — |
| Synexus | Glendale, Arizona, United States | — |
| Lenzmeier Family Practice | Glendale, Arizona, United States | — |
| Clinical Research Inst of Arizona | Sun City West, Arizona, United States | — |
| Clinical Research Advantage Fiel Family and Sports Med, PC | Tempe, Arizona, United States | — |
| Synexus Clinical Research US Inc | Tucson, Arizona, United States | — |
+ 971 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.